Evidence map›Paper›PMID 42047395›Full record

ArticleJournal of the American Chemical Society2026

Photoswitchable COX-2-Selective Inhibitors as Light-Regulated Anti-Inflammatory Agents.

Amanda Morales, Alejandro Cruz, Álex Pérez-Sánchez, Danilo D'Avino, Gaia Galassi, Erica Ginevra Milano, Irene Bernareggi, Carla Arenós-Bach, Giovanni Grazioso, Ramon Alibés and 8 more

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Amanda MoralesDepartament de Química, Universitat Autònoma de Barcelona, Bellaterra (Barcelona) 08193, Spain.
Alejandro CruzDepartament d'Enginyeria Química (EQ), ETSEIB, Universitat Politècnica de Catalunya - BarcelonaTech (UPC), Campus Sud, Edif. PG, Av. Diagonal, 647, Barcelona 08028, Spain.ORCID 0000-0003-0928-0718
Álex Pérez-SánchezDepartament de Química, Universitat Autònoma de Barcelona, Bellaterra (Barcelona) 08193, Spain.ORCID 0000-0003-3636-3885
Danilo D'AvinoDepartment of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples 80131, Italy.ORCID 0000-0002-6350-5191
Gaia GalassiDepartment of Medical Biotechnology and Translational Medicine, L.I.T.A., University of Milan, Via Fratelli Cervi 93, Segrate, Milano 20054, Italy.
Erica Ginevra MilanoDepartment of Pharmaceutical Sciences, University of Milan, Milan 20133, Italy.
Irene BernareggiDepartment of Pharmaceutical Sciences, University of Milan, Milan 20133, Italy.
Carla Arenós-BachDepartament de Química, Universitat Autònoma de Barcelona, Bellaterra (Barcelona) 08193, Spain.
Giovanni GraziosoDepartment of Pharmaceutical Sciences, University of Milan, Milan 20133, Italy.ORCID 0000-0002-3261-9356
Ramon AlibésDepartament de Química, Universitat Autònoma de Barcelona, Bellaterra (Barcelona) 08193, Spain.ORCID 0000-0002-7997-2691
Jordi HernandoDepartament de Química, Universitat Autònoma de Barcelona, Bellaterra (Barcelona) 08193, Spain.ORCID 0000-0002-1126-4138
Pau GorostizaCatalan Institution for Research and Advanced Studies (ICREA), Barcelona 08010, Spain.ORCID 0000-0002-7268-5577
Antonietta RossiDepartment of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples 80131, Italy.
Anna PistocchiDepartment of Medical Biotechnology and Translational Medicine, L.I.T.A., University of Milan, Via Fratelli Cervi 93, Segrate, Milano 20054, Italy.
Carlo MateraDepartment of Pharmaceutical Sciences, University of Milan, Milan 20133, Italy.ORCID 0000-0001-6939-3859
Félix BusquéDepartament de Química, Universitat Autònoma de Barcelona, Bellaterra (Barcelona) 08193, Spain.
Àngels González-LafontDepartament de Química, Universitat Autònoma de Barcelona, Bellaterra (Barcelona) 08193, Spain.ORCID 0000-0003-0729-2483
José M LluchDepartament de Química, Universitat Autònoma de Barcelona, Bellaterra (Barcelona) 08193, Spain.ORCID 0000-0002-7536-1869

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite their extensive use, the therapeutic potential of nonsteroidal anti-inflammatory drugs (NSAIDs) remains significantly constrained by adverse side effects. This limitation primarily arises from insufficient selectivity, as current NSAIDs inhibit not only the inducible cyclooxygenase-2 (COX-2) isoform at sites of inflammation but also constitutive COX-2 in healthy tissues and, frequently, cyclooxygenase-1. To address this challenge, we developed photoswitchable NSAIDs that combine COX-2 selectivity with light-controlled activity to enable spatiotemporal confinement of the therapeutic effect at inflamed tissues. Following computational design and screening of a library of azoaromatic derivatives of celecoxib─the most widely used COX-2 selective NSAID─three photoswitchable analogues were synthesized, which exhibited reversible and efficient

Indexed as

Anti-Inflammatory Agents, Non-SteroidalCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsLightAnimalsHumansInflammationMacrophagesMolecular StructurePhotochemical ProcessesZebrafishAnti-Inflammatory Agents, Non-SteroidalCelecoxibCyclooxygenase 2Cyclooxygenase 2 Inhibitors

Identifiers

PMID42047395
PMCPMC13209505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.